Díaz-Vico Tamara, Fernández-Martínez Daniel, García-Gutiérrez Carmen, Suárez-Sánchez Aida, Cifrián-Canales Isabel, Mendoza-Pacas Guillermo Eduardo, Sánchez-Farpón Herminio, Truán-Alonso Nuria
Department of General Surgery, Hospital Universitario Central de Asturias (HUCA), Oviedo, Asturias, Spain.
Department of Pathology, Hospital Universitario Central de Asturias (HUCA), Oviedo, Asturias, Spain.
J Gastrointest Oncol. 2019 Jun;10(3):589-596. doi: 10.21037/jgo.2019.01.11.
Mucinous adenocarcinoma (MA) is a rare entity. Indeed, the pathogenesis of fistula-associated perianal MA is still controversial. Due to the lack of informed evidence regarding this malignancy, no guidelines have been established concerning diagnostic and treatment strategies. The aim of this article is to report our experience and outcomes after three cases of large perianal MA treated in our center. From our retrospective chart review, we identified three male patients with chronic perianal fistula-in-ano who progressively developed perianal MA, confirmed by pelvic magnetic resonance (MRI) and histopathological examination performed on biopsy. We hereby, in accordance with the Surgical CAse REport (SCARE) guidelines, describe the management and further follow-up of each patient. The three patients underwent preoperative chemoradiation therapy, followed by ischioanal abdominoperineal resection (APR). Perineal reconstruction was needed in every case, using a vertical rectus abdominis myocutaneous (VRAM) flap and, punctually, a left fasciocutaneous flap was used too. Also, two of three patients completed the treatment with adjuvant chemotherapy. Neither recurrences nor distant metastases have been observed during the follow-up in both cases that finished the multimodal treatment. MA arising from chronic perianal fistula has an indolent growth with locoregional aggressiveness and a high risk of local recurrence. Therefore, although an ischioanal APR remains the surgical treatment of choice, an aggressive multimodal approach combining preoperative chemoradiation and adjuvant chemotherapy may achieve favorable effectiveness and promising response rates.
黏液腺癌(MA)是一种罕见的疾病。事实上,瘘管相关性肛周MA的发病机制仍存在争议。由于缺乏关于这种恶性肿瘤的充分证据,尚未制定有关诊断和治疗策略的指南。本文的目的是报告我们中心治疗3例大型肛周MA后的经验和结果。通过回顾性病历审查,我们确定了3例患有慢性肛管肛瘘的男性患者,他们逐渐发展为肛周MA,经盆腔磁共振成像(MRI)和活检的组织病理学检查确诊。在此,我们按照外科病例报告(SCARE)指南,描述每位患者的治疗及进一步随访情况。这3例患者均接受了术前放化疗,随后行坐骨肛管腹会阴联合切除术(APR)。每例患者均需要进行会阴重建,采用腹直肌肌皮瓣(VRAM),并适时使用左侧筋膜皮瓣。此外,3例患者中有2例完成了辅助化疗。在完成多模式治疗的2例患者的随访期间,均未观察到复发或远处转移。由慢性肛周瘘管引起的MA生长缓慢,但具有局部侵袭性且局部复发风险高。因此,尽管坐骨肛管APR仍然是首选的手术治疗方法,但术前放化疗和辅助化疗相结合的积极多模式方法可能会取得良好的疗效和有希望的缓解率。